Skip to main content

Advertisement

Log in

Current Trends in the Management of Beta Thalassemia

  • Symposium on Advances in Hematology
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

The management of Beta Thalassemia, the commonest form of hemolytic anemia in children, has changed significantly in the last few years. With the availability of better transfusion regimen, iron chelation therapy, proper management of complications and good supportive care, it is now possible for a thalassemic child to have a near normal life span with a good quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005; 1054: 445–450.

    Article  PubMed  Google Scholar 

  2. Pignatti CB, Rugolotto S, Stefano P, Piga A, Gregorio F, Gamberini M et al. Survival and Disease Complications in Thalassemia Major. Ann N Y Acad Sci 1998; 850: 227–231.

    Article  Google Scholar 

  3. Guidelines for the Clinical Management of Thalassemia. Thalassemia international federation (TIF) 2007.

  4. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassemia. Cochrane Database Syst Rev 2005 19: CD004450.

  5. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2005 Dec 22; [Epub ahead of print]

  6. Porter J, Vichinsky E, Rose C, Piga A, Olivieri N, Gattermann N et al. A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload. Blood 2004; 104: 872A–872A.

    Google Scholar 

  7. Vichinsky E, Fischer R, Fung E, Onyekwere O, Porter J, Swerdlow P et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade ((R)) ICL670) is well tolerated and reduces iron. Blood 2005; 106: 95A–95A.

    Article  CAS  Google Scholar 

  8. Piga A, Galanello R, Cappellini MD, Forni GL, Lupo G, Ford JM et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmaco kinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 2003; 102: 121A–121A.

    Google Scholar 

  9. Piga A, Galanello R, Foschini ML, Zappu A, Bordone E, Longo F et al. Once-daily treatment with the oral iron chelator ICL670 (Exjade (R): Results of a phase II study in pediatric patients with beta thalassernia major. Blood 2004; 104: 983A–983A.

    Google Scholar 

  10. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with ta-thalassemia. Blood 2006; 107: 3455–3462.

    Google Scholar 

  11. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessý C. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90: 1309–1314.

    PubMed  CAS  Google Scholar 

  12. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta thalassemia. Lancet 2002; 360: 516–520.

    Article  PubMed  CAS  Google Scholar 

  13. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M et al. Endocrine complications of thalassemia. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders 2003; 3: 4.

    Article  PubMed  Google Scholar 

  14. De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004; 2: 249–255.

    PubMed  Google Scholar 

  15. Wu KH, Tsai FJ, Peng CT. Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment. Ann Hematol 2003; 82: 540–637.

    Article  CAS  Google Scholar 

  16. Chern J P S, Lin K H, Lu M Y, Lin D T, Lin K S, Chen JD et al. Abnormal Glucose Tolerance in Transfusion-Dependent β-Thalassemic Patients. Diabetes Care 2001; 24: 850–854.

    Article  PubMed  CAS  Google Scholar 

  17. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with Thalassaemia Major. J Clin Endocrinol Metab 1993; 77: 478–483.

    Article  PubMed  CAS  Google Scholar 

  18. Venti S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006; 6: 226–233.

    Article  Google Scholar 

  19. Tsiantis J, Xypolita-Tsantili D, Papadakou-Lagoyianni S. Family reactions and their management in a parents group with beta-thalassemia. Arch Dis Child 1982; 57: 860–863.

    Article  PubMed  CAS  Google Scholar 

  20. Shaligram D, Girimaji SC, Chaturvedi SK. Psychological problems and quality of life in children with thalassemia Indian J Pediatr 2007; 74: 727–730.

    Article  PubMed  CAS  Google Scholar 

  21. Pafumi C, Farina M, Pernicone G et al. At term pregnancies in transfusion-dependent beta-thalassemic women. Clin Exp Obstet Gynecol 2000; 27: 185–187.

    PubMed  CAS  Google Scholar 

  22. Skordis N, Christou S, Koliou M, Pavlides N, Angastiniotis M. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 935–943.

    PubMed  Google Scholar 

  23. Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 945–951.

    PubMed  Google Scholar 

  24. Cunningham MJ, Macklin EA, Muraca G, Neufeld EJ. Successful pregnancy in thalassemia major women in the Thalassemia Clinical Research Network. Pediatr Res 2004; 55: 294.

    Google Scholar 

  25. Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf) 2000; 53: 33–42.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. P. Dubey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dubey, A.P., Parakh, A. & Dublish, S. Current Trends in the Management of Beta Thalassemia. Indian J Pediatr 75, 739–743 (2008). https://doi.org/10.1007/s12098-008-0140-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-008-0140-4

Key words

Navigation